[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201490384A1 - Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности - Google Patents

Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности

Info

Publication number
EA201490384A1
EA201490384A1 EA201490384A EA201490384A EA201490384A1 EA 201490384 A1 EA201490384 A1 EA 201490384A1 EA 201490384 A EA201490384 A EA 201490384A EA 201490384 A EA201490384 A EA 201490384A EA 201490384 A1 EA201490384 A1 EA 201490384A1
Authority
EA
Eurasian Patent Office
Prior art keywords
kidney damage
complex
compositions
methods
kda
Prior art date
Application number
EA201490384A
Other languages
English (en)
Inventor
Джозеф Андерберг
Джефф Грей
Пол Макферсон
Кевин Накамура
Джеймс Патрик Кампф
Original Assignee
Астьют Медикал, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астьют Медикал, Инк. filed Critical Астьют Медикал, Инк.
Publication of EA201490384A1 publication Critical patent/EA201490384A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Surgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)

Abstract

Изобретение относится к способам и композициям для наблюдения за состоянием, диагностики, прогнозирования и определения схемы лечения субъектов, страдающих повреждением почек или предположительно имеющих повреждение почек. В частности, настоящее изобретение относится к применению одного или более анализа, позволяющего обнаружить маркер повреждения почек, выбранный из группы, состоящей из белка теплового шока 1 массой 70 кДа, комплекса альфа-1-антитрипсин/ нейтрофил-эластазы, комплекса стромелизина-1 - ингибитора металлопротеиназы 2, комплекса коллагеназы типа IV массой 72 кДа - ингибитора металлопротеиназы 2, рецептора инсулиноподобного фактора роста 1, белка первичного ответа миелоидной дифференциации MyD88, адгезионной молекулы нервной клетки и члена суперсемейства лигандов фактора некроза опухоли 10, в качестве диагностических и прогностических биомаркеров при повреждениях почек.
EA201490384A 2011-08-26 2012-08-24 Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности EA201490384A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161528000P 2011-08-26 2011-08-26
US201161528003P 2011-08-26 2011-08-26
PCT/US2012/052298 WO2013043310A1 (en) 2011-08-26 2012-08-24 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (1)

Publication Number Publication Date
EA201490384A1 true EA201490384A1 (ru) 2014-08-29

Family

ID=47914751

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490384A EA201490384A1 (ru) 2011-08-26 2012-08-24 Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности

Country Status (16)

Country Link
US (2) US9459261B2 (ru)
EP (2) EP2748605B1 (ru)
JP (2) JP2014529073A (ru)
KR (1) KR20140074307A (ru)
CN (2) CN103874923B (ru)
AU (1) AU2012312907A1 (ru)
BR (1) BR112014004389A2 (ru)
CA (1) CA2846602A1 (ru)
EA (1) EA201490384A1 (ru)
ES (1) ES2721907T3 (ru)
IN (1) IN2014MN00377A (ru)
MX (1) MX346096B (ru)
PL (1) PL2748605T3 (ru)
PT (1) PT2748605T (ru)
TR (1) TR201903235T4 (ru)
WO (1) WO2013043310A1 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101760314B1 (ko) 2008-10-21 2017-07-21 아스튜트 메디컬 인코포레이티드 신손상 및 신부전의 진단 및 예후 예측을 위한 방법 및 조성물
ES2818138T3 (es) 2009-12-20 2021-04-09 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
EP3339860A1 (en) 2010-06-23 2018-06-27 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EA201490384A1 (ru) * 2011-08-26 2014-08-29 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EP2788759B1 (en) 2011-12-08 2019-02-20 Astute Medical, Inc. Methods and uses for diagnosis of renal injury and renal failure
CN105074466B (zh) 2013-01-17 2018-01-09 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
ES2696075T3 (es) 2013-01-28 2019-01-14 Diasorin S P A Procedimiento y kit para detectar 1,25-dihidroxivitamina D y anticuerpos relacionados
US11261257B2 (en) 2013-01-28 2022-03-01 Diasorin S.P.A. Methods for detecting 1,25-dihydroxyvitamin D and related antibodies
US10983136B2 (en) 2013-01-28 2021-04-20 Diasorin S.P.A. Use of 1,25-dihydroxyvitamin D values in ratio with PTH as a prognostic biomarker
EP3077819A4 (en) 2013-12-03 2017-06-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2016064877A2 (en) * 2014-10-20 2016-04-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3245515A1 (en) * 2015-01-18 2017-11-22 DiaSorin S.p.A. Use of 1,25-dihydroxyvitamin d values in ratio with pth as a prognostic biomarker
EP3281011B1 (en) 2015-04-09 2024-06-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN105466984B (zh) * 2016-01-14 2018-12-28 郑以山 用于肾脏非显性损伤的预警装置及其使用方法
CN109844526A (zh) 2016-06-06 2019-06-04 机敏医药股份有限公司 使用胰岛素样生长因子结合蛋白7和金属蛋白酶2的组织抑制剂管理急性肾损伤
CN110651187A (zh) 2017-01-12 2020-01-03 机敏医药股份有限公司 基于c-c基序趋化因子配体14测量结果评价和治疗肾损伤和肾衰竭的方法和组合物
WO2018145117A1 (en) 2017-02-06 2018-08-09 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2018187453A1 (en) 2017-04-05 2018-10-11 Astute Medical, Inc. Assays for timp2 having improved performance in biological samples
CA3101470A1 (en) 2018-05-24 2019-11-28 Renibus Therapeutics, Inc. Methods of treating patients at risk for renal injury and renal failure
CN109251956A (zh) * 2018-09-18 2019-01-22 青岛大学 糖尿病大鼠胰岛内MyD88 mRNA表达及黄芪的调节作用
WO2020092909A1 (en) * 2018-11-02 2020-05-07 Prevencio, Inc. Prognostic and diagnostic methods for risk of acute kidney injury
CN114113575B (zh) * 2020-08-28 2023-06-02 菲鹏生物股份有限公司 标记复合物及其制备方法与应用
CN116434960B (zh) * 2023-06-13 2023-10-13 中国人民解放军总医院 一种心源性休克临床决策支持系统、设备及可存储介质

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
JPH05504841A (ja) 1990-09-14 1993-07-22 バイオサイト・ダイアグノスティックス・インコーポレイテッド リガンドレセプター及びリガンドのコンプレックスに対する抗体及びリガンド―レセプターアッセーでのそれらの用途
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
DE69228682T2 (de) 1991-04-10 1999-07-01 Biosite Diagnostics Inc., San Diego, Calif. "crosstalk"- oder übersprech-inhibitoren und ihre verwendung
CA2107899A1 (en) 1991-04-10 1992-10-11 Gunars Edwin Valkirs Novel conjugates and assays for simultaneous detection of multiple ligands
US5324634A (en) * 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
ES2754753T3 (es) 2003-03-27 2020-04-20 Childrens Hospital Med Ct Un método y kit para la detección de la instauración precoz de la lesión de células tubulares renales
CN1791797A (zh) * 2003-03-27 2006-06-21 儿童医院医疗中心 用于检测肾小管细胞损伤的早发的方法和试剂盒
WO2005002416A2 (en) * 2003-06-04 2005-01-13 Joslin Diabetes Center, Inc. Predictors of renal disease
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
US20060003345A1 (en) * 2004-06-30 2006-01-05 Pfizer Inc RNA bioassay
CN101557825A (zh) * 2005-08-19 2009-10-14 森托科尔公司 抗蛋白酶解的抗体制剂
WO2007144781A2 (en) * 2006-04-21 2007-12-21 Diagnotech Pty. Ltd. Diagnostic methods and kits utilizing antibodies for metalloproteases
BRPI0809432A2 (pt) * 2007-03-26 2014-09-09 Novartis Ag Biomarcadores de segurança renal preditivos e assinaturas de biomarcadores para monitorar a função renal
US20100304413A1 (en) 2007-11-15 2010-12-02 Lars Otto Uttenthal Diagnostic use of individual molecular forms of a biomarker
BRPI0907802A2 (pt) * 2008-02-29 2016-08-23 Univ Nagoya Nat Univ Corp biomarcador para lesão renal aguda e estimativa de seu prognóstico, e sua aplicação
JP2012501456A (ja) * 2008-08-28 2012-01-19 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
CA2735590A1 (en) * 2008-08-29 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR101760314B1 (ko) * 2008-10-21 2017-07-21 아스튜트 메디컬 인코포레이티드 신손상 및 신부전의 진단 및 예후 예측을 위한 방법 및 조성물
EP2913676A1 (en) * 2008-11-10 2015-09-02 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) * 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2012529015A (ja) * 2009-06-02 2012-11-15 バイオクラテス ライフ サイエンシーズ アーゲー 腎臓疾患評価用新規バイオマーカー
MX336280B (es) * 2009-08-07 2016-01-13 Astute Medical Inc Metodos y composiciones para diagnosticos y pronosticos de lesion renal y falla renal.
US20130045494A1 (en) * 2009-09-18 2013-02-21 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2009012633A (es) * 2009-11-23 2011-05-24 Univ Mexico Nacional Autonoma Metodo de diagnostico para detectar la lesion renal aguda a traves del uso de la proteina de choque termico de 72 kda como un biomarcador sensible.
ES2818138T3 (es) * 2009-12-20 2021-04-09 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
NZ602056A (en) * 2010-02-26 2014-11-28 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EA201490384A1 (ru) * 2011-08-26 2014-08-29 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности

Also Published As

Publication number Publication date
AU2012312907A1 (en) 2014-03-13
CN103874923A (zh) 2014-06-18
CN106443011A (zh) 2017-02-22
EP2748605B1 (en) 2018-12-05
EP3489690A1 (en) 2019-05-29
US9784750B2 (en) 2017-10-10
NZ706242A (en) 2016-07-29
TR201903235T4 (tr) 2019-03-21
EP2748605A1 (en) 2014-07-02
CA2846602A1 (en) 2013-03-28
JP2014529073A (ja) 2014-10-30
WO2013043310A1 (en) 2013-03-28
MX2014002146A (es) 2014-08-21
NZ621716A (en) 2016-04-29
PT2748605T (pt) 2019-05-03
JP2017032586A (ja) 2017-02-09
MX346096B (es) 2017-03-07
IN2014MN00377A (ru) 2015-06-19
KR20140074307A (ko) 2014-06-17
US9459261B2 (en) 2016-10-04
EP2748605A4 (en) 2015-12-02
ES2721907T3 (es) 2019-08-06
US20140213477A1 (en) 2014-07-31
PL2748605T4 (pl) 2019-08-30
BR112014004389A2 (pt) 2017-03-28
CN103874923B (zh) 2016-09-14
PL2748605T3 (pl) 2019-08-30
US20170016917A1 (en) 2017-01-19

Similar Documents

Publication Publication Date Title
EA201490384A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EA201290711A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EA201290629A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EA201290056A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EA201290387A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EA201291314A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
NZ592358A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure using tissue inhibitor of metalloproteinase 2 (timp-2)
NZ599105A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX351779B (es) Prediccion de neoplasmas neuroendocrinos gastroenteropancreaticos (gep-nens).
NZ605698A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EA201490105A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
US20220252617A1 (en) Biomarkers of fast progression of chronic kidney disease
EA201290192A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
EA201390150A1 (ru) Способы выявления сигнатур заболевания или патологических состояний в текучих средах организма
EA201391187A1 (ru) Способ диагностики злокачественной опухоли и набор для диагностики путем измерения активности nk-клеток
EA201370063A1 (ru) Фосфолипидом рака
MY162697A (en) Methods, devices and kits for detecting or monitoring acute kidney injury
EA201290106A1 (ru) Способы и композиции для диагностики и прогнозирования повреждения почек и почечной недостаточности
EA201290627A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
RU2017115663A (ru) Способы и системы для отличия синдрома раздраженного кишечника от воспалительного заболевания кишечника и глютеновой болезни
EP2415877A3 (en) Means and methods for diagnosing pancreatic cancer
EA201290948A1 (ru) МАРКЕРЫ HbF И A1M В КАЧЕСТВЕ МАРКЕРОВ РАННЕЙ СТАДИИ ПРЕЭКЛАМПСИИ
NZ703055A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ601643A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure